JP2008526764A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008526764A5 JP2008526764A5 JP2007549646A JP2007549646A JP2008526764A5 JP 2008526764 A5 JP2008526764 A5 JP 2008526764A5 JP 2007549646 A JP2007549646 A JP 2007549646A JP 2007549646 A JP2007549646 A JP 2007549646A JP 2008526764 A5 JP2008526764 A5 JP 2008526764A5
- Authority
- JP
- Japan
- Prior art keywords
- primary
- epitope
- mhc
- immunogen
- antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US64082104P | 2004-12-29 | 2004-12-29 | |
| PCT/US2005/047442 WO2006071990A2 (en) | 2004-12-29 | 2005-12-29 | Methods to bypass cd+4 cells in the induction of an immune response |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008526764A JP2008526764A (ja) | 2008-07-24 |
| JP2008526764A5 true JP2008526764A5 (https=) | 2009-02-26 |
Family
ID=36615526
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007549646A Pending JP2008526764A (ja) | 2004-12-29 | 2005-12-29 | 免疫応答の誘導におけるｃｄ４＋細胞の回避方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8703142B2 (https=) |
| EP (1) | EP1838342A2 (https=) |
| JP (1) | JP2008526764A (https=) |
| AU (1) | AU2005321905A1 (https=) |
| CA (1) | CA2592972A1 (https=) |
| IL (1) | IL184276A0 (https=) |
| MX (1) | MX2007008010A (https=) |
| SG (1) | SG158155A1 (https=) |
| WO (1) | WO2006071990A2 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6977074B2 (en) * | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
| DE10347710B4 (de) | 2003-10-14 | 2006-03-30 | Johannes-Gutenberg-Universität Mainz | Rekombinante Impfstoffe und deren Verwendung |
| NZ564359A (en) | 2005-06-17 | 2011-09-30 | Mannkind Corp | Analogs of pepetides corresponding to class I MHC-restricted T cell epitopes |
| SG162817A1 (en) | 2005-06-17 | 2010-07-29 | Mannkind Corp | Methods and compositions.to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| WO2008054540A2 (en) | 2006-05-18 | 2008-05-08 | Pharmexa Inc. | Inducing immune responses to influenza virus using polypeptide and nucleic acid compositions |
| JP2009544610A (ja) * | 2006-07-14 | 2009-12-17 | マンカインド コーポレイション | 予防又は治療目的のためにｍｈｃクラスｉ拘束エピトープに対する免疫応答を引き出し、増強し、保持する方法 |
| CN103736086A (zh) * | 2007-02-15 | 2014-04-23 | 曼康公司 | 用于增强t细胞应答的方法 |
| WO2008116468A2 (en) | 2007-03-26 | 2008-10-02 | Dako Denmark A/S | Mhc peptide complexes and uses thereof in infectious diseases |
| WO2008148068A1 (en) * | 2007-05-23 | 2008-12-04 | Mannkind Corporation | Multicistronic vectors and methods for their design |
| EP3620465B1 (en) | 2007-07-03 | 2025-02-19 | Dako Denmark A/S | Improved methods for generation, labeling and use of mhc multimers |
| US10611818B2 (en) | 2007-09-27 | 2020-04-07 | Agilent Technologies, Inc. | MHC multimers in tuberculosis diagnostics, vaccine and therapeutics |
| DK2254592T3 (da) | 2008-02-28 | 2019-09-09 | Dako Denmark As | MHC-multimerer til Borrelia-diagnostik og sygdom |
| WO2010009735A2 (en) | 2008-07-23 | 2010-01-28 | Dako Denmark A/S | Combinatorial analysis and repair |
| GB0817244D0 (en) | 2008-09-20 | 2008-10-29 | Univ Cardiff | Use of a protein kinase inhibitor to detect immune cells, such as T cells |
| US11992518B2 (en) | 2008-10-02 | 2024-05-28 | Agilent Technologies, Inc. | Molecular vaccines for infectious disease |
| WO2010037402A1 (en) | 2008-10-02 | 2010-04-08 | Dako Denmark A/S | Molecular vaccines for infectious disease |
| US20110195090A1 (en) * | 2008-10-11 | 2011-08-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human | Method of making a vaccine |
| AU2010310468A1 (en) | 2009-10-23 | 2012-05-24 | Mannkind Corporation | Cancer immunotherapy and method of treatment |
| PL3892295T3 (pl) | 2011-05-24 | 2023-07-24 | BioNTech SE | Zindywidualizowane szczepionki przeciwnowotworowe |
| WO2013143555A1 (en) | 2012-03-26 | 2013-10-03 | Biontech Ag | Rna formulation for immunotherapy |
| EP3417874B1 (en) | 2012-11-28 | 2024-09-11 | BioNTech SE | Individualized vaccines for cancer |
| WO2014180490A1 (en) | 2013-05-10 | 2014-11-13 | Biontech Ag | Predicting immunogenicity of t cell epitopes |
| WO2015199617A1 (en) * | 2014-06-24 | 2015-12-30 | National University Of Singapore | A monoclonal antibody with t-cell receptor-like specificity that targets epstein-barr infected human tumour cells based on their expression of ebna1 |
| WO2016045732A1 (en) | 2014-09-25 | 2016-03-31 | Biontech Rna Pharmaceuticals Gmbh | Stable formulations of lipids and liposomes |
| WO2016128060A1 (en) | 2015-02-12 | 2016-08-18 | Biontech Ag | Predicting t cell epitopes useful for vaccination |
| TW201702272A (zh) * | 2015-05-22 | 2017-01-16 | 美國紀念斯隆 凱特琳癌症中心 | Ｐｒａｍｅ肽專一性類ｔ細胞受體抗體 |
| WO2017059902A1 (en) | 2015-10-07 | 2017-04-13 | Biontech Rna Pharmaceuticals Gmbh | 3' utr sequences for stabilization of rna |
| WO2018224166A1 (en) | 2017-06-09 | 2018-12-13 | Biontech Rna Pharmaceuticals Gmbh | Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy |
| WO2020127222A2 (en) | 2018-12-17 | 2020-06-25 | Immudex Aps | Panel comprising borrelia mhc multimers |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1247080A (en) | 1983-03-08 | 1988-12-20 | Commonwealth Serum Laboratories Commission | Antigenically active amino acid sequences |
| US6994851B1 (en) | 1997-07-10 | 2006-02-07 | Mannkind Corporation | Method of inducing a CTL response |
| US6977074B2 (en) * | 1997-07-10 | 2005-12-20 | Mannkind Corporation | Method of inducing a CTL response |
| ES2265165T3 (es) * | 1997-07-10 | 2007-02-01 | Mannkind Corporation | Dispositivo para inducir una respuesta ltc. |
| US6709844B1 (en) | 2000-11-16 | 2004-03-23 | Mannkind Corporation | Avoidance of undesirable replication intermediates in plasmid propagation |
| US20030138808A1 (en) | 1998-02-19 | 2003-07-24 | Simard John J.L. | Expression vectors encoding epitopes of target-associated antigens |
| US6656471B1 (en) | 1998-11-17 | 2003-12-02 | Board Of Regents, The University Of Texas System | HIV-specific T-cell induction |
| EP1267618A1 (en) | 2000-03-28 | 2003-01-02 | The Regents Of The University Of California | Methods for increasing a cytotoxic t lymphocyte response in vivo |
| DK1276896T3 (da) | 2000-04-28 | 2010-10-18 | Mannkind Corp | Epitop-synkronisering i antigen-præsenterende celler |
| US20030215425A1 (en) | 2001-12-07 | 2003-11-20 | Simard John J. L. | Epitope synchronization in antigen presenting cells |
| US6861234B1 (en) | 2000-04-28 | 2005-03-01 | Mannkind Corporation | Method of epitope discovery |
| US7252824B2 (en) | 2001-03-07 | 2007-08-07 | Mannkind Corporation | Anti-neovasculature preparations for cancer |
| WO2003008537A2 (en) | 2001-04-06 | 2003-01-30 | Mannkind Corporation | Epitope sequences |
| CN101024842A (zh) | 2001-11-07 | 2007-08-29 | 曼康公司 | 编码靶相关抗原表位的表达载体及其设计方法 |
| AU2003270311A1 (en) | 2002-09-06 | 2004-03-29 | Mannkind Corporation | Epitope sequences |
| AU2004249254B2 (en) | 2003-06-17 | 2010-07-08 | Mannkind Corporation | Combinations of tumor-associated antigens for the treatment of various types of cancers |
| DK1635863T3 (da) * | 2003-06-17 | 2010-11-22 | Mannkind Corp | Sammensætninger til udløsning, forbedring og opretholdelse af immunresponser mod MHC-klasse-i-begrænsede epitoper til profylaktiske eller terapeutiske formål |
| CA2571168A1 (en) | 2004-06-17 | 2006-01-26 | Mannkind Corporation | Mhc i-binding ssx-241-49 variants |
| US20060159689A1 (en) | 2004-06-17 | 2006-07-20 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in diagnostics for various types of cancers |
| US20060008468A1 (en) | 2004-06-17 | 2006-01-12 | Chih-Sheng Chiang | Combinations of tumor-associated antigens in diagnostics for various types of cancers |
| US20050287068A1 (en) | 2004-06-17 | 2005-12-29 | Bot Adrian I | Efficacy of active immunotherapy by integrating diagnostic with therapeutic methods |
| PL1833506T3 (pl) | 2004-12-29 | 2016-01-29 | Mannkind Corp | Zastosowanie kompozycji zawierających różne antygeny związane z nowotworem jako szczepionek przeciwnowotworowych |
| JP2008526763A (ja) | 2004-12-29 | 2008-07-24 | マンカインド コーポレイション | 予防又は治療目的のｍｈｃクラスｉ拘束性エピトープに対する免疫応答の誘導、増強及び保持方法 |
| EP1838338A2 (en) | 2004-12-29 | 2007-10-03 | Mannkind Corporation | Methods to trigger, maintain and manipulate immune responses by targeted administration of biological response modifiers into lymphoid organs |
| NZ564359A (en) | 2005-06-17 | 2011-09-30 | Mannkind Corp | Analogs of pepetides corresponding to class I MHC-restricted T cell epitopes |
| SG162817A1 (en) | 2005-06-17 | 2010-07-29 | Mannkind Corp | Methods and compositions.to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma |
| AU2006259221B8 (en) | 2005-06-17 | 2013-02-07 | Mannkind Corporation | Multivalent entrain-and-amplify immunotherapeutics for carcinoma |
| JP2009544610A (ja) | 2006-07-14 | 2009-12-17 | マンカインド コーポレイション | 予防又は治療目的のためにｍｈｃクラスｉ拘束エピトープに対する免疫応答を引き出し、増強し、保持する方法 |
-
2005
- 2005-12-29 CA CA002592972A patent/CA2592972A1/en not_active Abandoned
- 2005-12-29 EP EP05855931A patent/EP1838342A2/en not_active Withdrawn
- 2005-12-29 WO PCT/US2005/047442 patent/WO2006071990A2/en not_active Ceased
- 2005-12-29 AU AU2005321905A patent/AU2005321905A1/en not_active Abandoned
- 2005-12-29 US US11/323,520 patent/US8703142B2/en not_active Expired - Fee Related
- 2005-12-29 MX MX2007008010A patent/MX2007008010A/es not_active Application Discontinuation
- 2005-12-29 JP JP2007549646A patent/JP2008526764A/ja active Pending
- 2005-12-29 SG SG200908487-2A patent/SG158155A1/en unknown
-
2007
- 2007-06-28 IL IL184276A patent/IL184276A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008526764A5 (https=) | ||
| Barnett et al. | Vaccination with HIV-1 gp120 DNA induces immune responses that are boosted by a recombinant gp120 protein subunit | |
| Corey et al. | Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen | |
| Cristillo et al. | Induction of mucosal and systemic antibody and T-cell responses following prime–boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations | |
| Goepfert et al. | High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects | |
| Gómez-Román et al. | An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains | |
| Fast et al. | Human trials of experimental AIDS vaccines | |
| Jiang et al. | CD8+ T-cell-mediated cross-clade protection in the genital tract following intranasal immunization with inactivated human immunodeficiency virus antigen plus CpG oligodeoxynucleotides | |
| Cristillo et al. | Preclinical evaluation of cellular immune responses elicited by a polyvalent DNA prime/protein boost HIV-1 vaccine | |
| Zolla-Pazner et al. | Neutralization of a clade B primary isolate by sera from human immunodeficiency virus-uninfected recipients of candidate AIDS vaccines | |
| US8338582B2 (en) | Anti-HIV immunogens and methods for inducing an immune response | |
| Koff et al. | Human trials of AIDS vaccines: current status and future directions | |
| Flynn et al. | Factors influencing cellular immune responses to feline immunodeficiency virus induced by DNA vaccination | |
| Launay et al. | Cellular immune responses induced with dose-sparing intradermal administration of HIV vaccine to HIV-uninfected volunteers in the ANRS VAC16 trial | |
| Flynn et al. | Induction of feline immunodeficiency virus-specific cell-mediated and humoral immune responses following immunization with a multiple antigenic peptide from the envelope V3 domain | |
| Edgeworth et al. | Vaccine development against HIV-1: current perspectives and future directions | |
| Luo et al. | Eliciting broad neutralizing antibody to HIV-1: envelopes of different lentivirus cross immunization by prime-boost vaccination | |
| Stott | Towards a vaccine against AIDS: lessons from simian immunodeficiency virus vaccines | |
| Lockey et al. | Multi-envelope HIV vaccine safety and immunogenicity in small animals and chimpanzees | |
| Mohan et al. | Comparative mucosal immunogenicity of HIV gp41 membrane-proximal external region (MPER) containing single and multiple repeats of ELDKWA sequence with defensin peptides | |
| Tramont et al. | Progress in the development of an HIV vaccine | |
| Temchura et al. | The two faces of vaccine-induced immune response: protection or increased risk of HIV infection?! | |
| Bazhan et al. | A synergistic effect of a combined bivalent DNA–protein anti-HIV-1 vaccine containing multiple T-and B-cell epitopes of HIV-1 proteins | |
| Silvera et al. | Vaccination with gp120-depleted HIV-1 plus immunostimulatory CpG oligodeoxynucleotides in incomplete Freund's adjuvant stimulates cellular and humoral immunity in rhesus macaques | |
| Ruffin et al. | Rational design of HIV vaccines and microbicides: report of the EUROPRISE annual conference 2011 |